Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with leukemia in Low-Income countries

NCT ID NCT04794296

Disease control Sponsor: French Africa Pediatric Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment plan for children with acute lymphoblastic leukemia (ALL) in low- and middle-income African countries. The plan uses stronger chemotherapy for high-risk cases and aims for an 85% remission rate. Researchers will track whether the drugs are available and if families can stick with the treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chemotherapy (anthracycline, Endoxan, Methotrexate)
What this could lead to
If successful, this could provide a practical, effective treatment protocol for childhood leukemia in resource-limited settings, improving survival rates.
What could go wrong
This is an early feasibility study in low-income countries, so drug availability and adherence may be challenging. The 85% remission target is ambitious and may not be reached.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

0 to 18 years of age presenting for treatment in any of the unit selected to carry out the recommandations

Ages

Up to 18 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2 \- Exclusion Criteria: ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia childhood acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Childhood ALL

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Donka 030 BP 554

    RECRUITING

    Conakry, Guinea

  • CHU de Treichville à ABIDJAN

    RECRUITING

    Abidjan, Côte d’Ivoire

  • Hôpital Aristide Le Dantec, Avenue Pasteur,

    RECRUITING

    Dakar, BP 3001, Senegal

More trials for these conditions

Other studies related to the condition(s) this trial covers.